KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 969.84%.

  • Xenon Pharmaceuticals' EBIT Margin changed N/A to 969.84% in Q1 2025 from the same period last year, while for Sep 2025 it was 4543.73%, marking a year-over-year change of. This contributed to the annual value of 1368.91% for FY2022, which is 9404600.0% down from last year.
  • As of Q1 2025, Xenon Pharmaceuticals' EBIT Margin stood at 969.84%.
  • Xenon Pharmaceuticals' 5-year EBIT Margin high stood at 198.14% for Q1 2022, and its period low was 28884.85% during Q3 2022.
  • Moreover, its 3-year median value for EBIT Margin was 817.25% (2021), whereas its average is 4762.84%.
  • Data for Xenon Pharmaceuticals' EBIT Margin shows a peak YoY increase of 1703500bps (in 2022) and a maximum YoY decrease of -285382300bps (in 2022) over the last 5 years.
  • Quarter analysis of 3 years shows Xenon Pharmaceuticals' EBIT Margin stood at 664.65% in 2021, then plummeted by -4246bps to 28884.85% in 2022, then skyrocketed by 97bps to 969.84% in 2025.
  • Its EBIT Margin was 969.84% in Q1 2025, compared to 28884.85% in Q3 2022 and 5655.78% in Q2 2022.